126 related articles for article (PubMed ID: 16200908)
1. [Should cholesterol levels be reduced more aggressively?].
Ravnskov U
Lakartidningen; 2005 Sep 12-18; 102(37):2583-4; discussion 2584. PubMed ID: 16200908
[No Abstract] [Full Text] [Related]
2. [The TNT debate gives a lift to the debate about high-dose statins. Lower LDL cholesterol levels further reduce the cardiovascular risk].
Olsson AG
Lakartidningen; 2005 May 2-15; 102(18-19):1393-4. PubMed ID: 15929421
[No Abstract] [Full Text] [Related]
3. [Misleading advice on cholesterol reduction].
Ravnskov U
Lakartidningen; 2006 Feb 22-28; 103(8):568; discussion 569. PubMed ID: 16570784
[No Abstract] [Full Text] [Related]
4. [Target levels for LDL cholesterol are put out of the running. Cholesterol should be lowered maximally in high cardiovascular risk].
Olsson AG
Lakartidningen; 2011 Jun 1-14; 108(22-23):1240-3. PubMed ID: 21786498
[No Abstract] [Full Text] [Related]
5. [The lower LDL cholesterol the better!].
Stenestrand U; Olsson AG
Lakartidningen; 2004 Oct; 101(42):3246-7. PubMed ID: 15544130
[No Abstract] [Full Text] [Related]
6. [Can higher level of HDL cholesterol augment cardiovascular disease prevention? The combination statins-nicotinic acid increases the level of HDL and reduces the level of LDL cholesterol].
Carlson LA
Lakartidningen; 2006 Oct 25-31; 103(43):3283-5. PubMed ID: 17117660
[No Abstract] [Full Text] [Related]
7. [Better with lower LDL cholesterol! Aim at 2 mmol/l for secondary prevention].
Olsson AG
Lakartidningen; 2006 Jan 11-17; 103(1-2):22-3. PubMed ID: 16465841
[No Abstract] [Full Text] [Related]
8. Should women with normal cholesterol be taking a statin? A major study suggests that statins also quell inflammation. Now what?
Harv Womens Health Watch; 2009 Feb; 16(6):1-3. PubMed ID: 19297742
[No Abstract] [Full Text] [Related]
9. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials.
Wei ZH; Wang H; Chen XY; Wang BS; Rong ZX; Wang BS; Su BH; Chen HZ
Eur J Clin Nutr; 2009 Jul; 63(7):821-7. PubMed ID: 18985059
[TBL] [Abstract][Full Text] [Related]
10. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
11. Is there a problem with ezetimibe or just ENHANCEd hype?
Whayne TF
Angiology; 2008 Dec-2009 Jan; 59(6):661-3. PubMed ID: 18796445
[No Abstract] [Full Text] [Related]
12. [High dosage stain protects heart and brain from recurrence].
MMW Fortschr Med; 2008 Nov; 150(48):118-9. PubMed ID: 19125516
[No Abstract] [Full Text] [Related]
13. [Lower and lower cholesterol targets increase adverse effects].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B; ;
Lakartidningen; 2009 Sep 30-Oct 6; 106(40):2550-1. PubMed ID: 19908628
[No Abstract] [Full Text] [Related]
14. [LDL lowering--level and time. Maybe two equally important parameters for protection against arteriosclerosis].
Herlitz J
Lakartidningen; 2006 Oct 25-31; 103(43):3272-3. PubMed ID: 17117658
[No Abstract] [Full Text] [Related]
15. [Lowering of LDL cholesterol prevents cardiovascular diseases. "Normal values" are too high--treatment time is a crucial factor].
Rudling M
Lakartidningen; 2006 Oct 25-31; 103(43):3278-82. PubMed ID: 17117659
[No Abstract] [Full Text] [Related]
16. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
Gotto AM; Farmer JA
Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
[TBL] [Abstract][Full Text] [Related]
17. [Type 2 diabetics are high risk patients. Concerning LDL-cholesterol to approach effectively to two sources].
MMW Fortschr Med; 2005 Nov; 147(44):52-3. PubMed ID: 16302495
[No Abstract] [Full Text] [Related]
18. [Lowering cholesterol: how low is low enough?].
Czuriga I; Edes I
Orv Hetil; 2006 Jul; 147(29):1349-56. PubMed ID: 16941825
[TBL] [Abstract][Full Text] [Related]
19. [New studies of high dosage statins and fibrates. How is lipid lowering therapy changing? (interview by Dr. med. Dirk Einecke)].
Klose G
MMW Fortschr Med; 2005 Dec; 147(49-50):20. PubMed ID: 16401005
[No Abstract] [Full Text] [Related]
20. In brief: Zetia and Vytorin: the ENHANCE study.
Med Lett Drugs Ther; 2008 Jan; 50(1278):5. PubMed ID: 18219263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
